摘要
脓毒症是由感染、手术、创伤等引起的全身炎症反应综合征(SIRS),死亡率高、治疗费用高、医疗资源消耗大,给医疗行业甚至是国家经济都带来了很大的负担,因此,找到治疗脓毒症的有效措施刻不容缓。目前针对脓毒症的发病机制,使用了一定的药物治疗,抗生素、糖皮质激素、血管活性药物等,但其治疗效果并不理想,副作用多,预后效果差,临床死亡率依然居高不下。中医讲究整体观念,辨证论治,对于脓毒症的治疗具有功效独特、副作用相对较小等优势,吸引了无数来自世界各地有志于解决脓毒症的科研及临床工作者们的目光。近年来,一些中药复方、中成药、单味中药及活性成分越来越多的作为新型药物用于预防、治疗脓毒症,并且得到了广泛的认可,在一定程度上降低了脓毒症患者的死亡率、炎性指标等,对于脓毒症的治疗起到了重要的作用。本文就核转录因子-κB(NF-κB)信号通路在脓毒症中的作用及以NF-κB信号通路相关蛋白为作用靶点的中药治疗脓毒症的研究进展进行综述。
Sepsis is a kind of systemic inflammatroy response syndrome( SIRS) induced by severe infection,operation,and trauma,with high mortality rate,treatment cost,and high consumption of medical resources. It has caused a great burden to the medical industry and even the national economy. Therefore,it is urgent to find effective treatment methods for sepsis. At present,the sepsis has been treated with certain drugs pointing at its pathogenesis,such as antibiotics,glucocorticoids,and vasoactive drugs.,but the therapeutic effect is not ideal,with many side effects,poor prognosis,and high clinical mortality. Based on the overall macrodialectical thinking mode,and with the unique effect and low side effect,traditional Chinese medicine( TCM) has attracted the attention from researchers and clinicians around the world for treatment of sepsis. In recent years,some traditional Chinese medicine prescriptions,Chinese patent medicines,single Chinese medicines and active ingredients are increasingly used as new drugs to prevent and treat sepsis. Such treatment methods have been widely recognized and have reduced the mortality and inflammatory indexes of patients to a certain extent,playing an important role in the prevention and treatment of sepsis. In this paper,the actions of nuclear factor kappa B( NF-κB) signal pathway in sepsis as well as the advances in research of NF-κB signal pathway-related proteins in Chinese medicine for sepsis were reviewed.
作者
苗雨露
张文智
张雯霞
冯敏
岳永花
聂春霞
倪艳
MIAO Yu-lu;ZHANG Wen-zhi;ZHANG Wen-xia;FENG Min;YUE Yong-hua;NIE Chun-xia;NI Yan(Shanxi Provincial Academy of Traditional Chinese Medicine, Taiyuan 030045,China;Shanxi University of Chinese Medicine,Taiyuan 030619,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2019年第9期214-220,共7页
Chinese Journal of Experimental Traditional Medical Formulae
基金
山西省重点研发计划项目(201603D321028)
关键词
核转录因子-ΚB
(NF-κB)信号通路
脓毒症
三证三法
中药复方
单味中药
中成药
nuclear factor kappa B (NF-κB) signal pathway
sepsis
three syndrome patterns and three treatments
compound Chinese materia
single herb
active ingredient
Chinese patent medicine
